Dr. Borea reviewed liquid biopsy screening for colorectal cancer. Multi-omics blood tests improved early detection and reduced late-stage diagnoses, with GALLERI and PATHFINDER 2 showing promising results.

Dr. Zakari reviewed ctDNA for MRD in colorectal cancer. NGS improved sensitivity, but evidence remains insufficient for routine ctDNA-guided therapy, and NCCN awaits more prospective trials.

The panel debated MRD testing, citing limited evidence, trial design concerns, and the need for stronger data. Multi-cancer blood tests show promise but should complement, not replace, standard screening.